SCHEMBL21685544

SCHEMBL21685544

CS(=O)(=O)OCc1nc2cccc(COc3ccc(F)cc3F)c2s1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHFR P00374 3/20 0.50
DCPS Q96C86 3/20 0.50
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
MAPK1 P28482 1/20 0.37
PTGER1 P34995 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
FFAR1 O14842 1/20 0.35
PKM P14618 2/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21685185 0.89 DHFR (0.41) DHFRDCPSPTGER1
SCHEMBL21685417 0.83 DHFR (0.56) DHFRDCPSALDH1A1KMT2AMEN1
SCHEMBL21684758 0.82 DHFR (0.50) DHFRDCPSALDH1A1KMT2AMEN1
SCHEMBL21684632 0.80 PTGER1 (0.37) DHFRDCPSPTGER1
SCHEMBL21684178 0.75 DHFR (0.50) DHFRDCPSALDH1A1KMT2AMEN1
SCHEMBL31304006 0.75 DHFR (0.50) DHFRDCPSALDH1A1KMT2AMEN1
SCHEMBL21685315 0.74 TLR8 (0.36) ALDH1A1KMT2AHPGDL3MBTL1MAPK1
SCHEMBL25947747 0.74 DHFR (0.43) DHFRDCPSALDH1A1KMT2AMEN1
SCHEMBL21684767 0.72 ALDH1A1 (0.47) DHFRDCPSALDH1A1KMT2AMEN1
SCHEMBL7543787 0.71 GFER (0.45) ALDH1A1KMT2AMEN1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219460-B1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA INC (US) 2025-02-26 EP disclosed
US-20250011324-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC., 2025-01-09 US disclosed
US-12152026-B2 Transglutaminase 2 (TG2) inhibitors SITARI PHARMA, INC. (US) 2024-11-26 US disclosed
EP-4219460-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS Sitari Pharma, Inc. (US) 2023-08-02 EP disclosed
US-11548892-B1 Transglutaminase 2 (TG2) inhibitors SITARI PHARMA, INC. (US) 2023-01-10 US disclosed
EP-3833348-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC (US) 2021-06-16 EP disclosed
US-20210163480-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC. 2021-06-03 US disclosed
WO-2020033784-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC. (US) 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163480-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS TGM2, TGM3, TGM1 DHFR 1119/4885DCPS 1646/4885ALDH1A1 4148/4885
US-11548892-B1 Transglutaminase 2 (TG2) inhibitors TGM2, TGM3, TGM1 DHFR 1119/4885DCPS 1646/4885ALDH1A1 4148/4885
US-12152026-B2 Transglutaminase 2 (TG2) inhibitors TGM2, TGM3, TGM1 DHFR 1119/4885DCPS 1646/4885ALDH1A1 4148/4885
US-20250011324-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS TGM2, TGM3, TGM1 DHFR 1119/4885DCPS 1646/4885ALDH1A1 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.